Advertisement

Tumor Biology

, Volume 35, Issue 1, pp 103–109 | Cite as

RETRACTED ARTICLE: Comprehensive assessment of the association between tumor necrosis factor alpha G238A polymorphism and liver cancer risk

  • Xin Tian
  • Ping Ma
  • Chengguang Sui
  • Yan Li
  • Liye Fu
  • Tao Jiang
  • Yang Wang
  • Youhong Jiang
Research Article

Abstract

Tumor necrosis factor alpha (TNF-α) has been suggested to play an important role in the development and liver cancer. TNF-α 238 G/A polymorphism was hypothesized to increase the risk of liver cancer, but findings from previous studies were controversial. To explore a more precise estimation of the relationship between TNF-α 238 G/A polymorphism and liver cancer, we performed a meta-analysis. PubMed, Embase, and China Biology Medicine databases were searched for all publications on this association through March 12, 2013. Odds ratios (ORs) with its 95 % confidence intervals (CIs) were used to assess the strength of this association. Eleven studies with 1,406 liver cancer cases and 2,386 noncancer controls were included into this meta-analysis. Overall, there was a significant association between TNF-α 238 G/A polymorphism and increased risk of liver cancer under all three genetic models (A vs. G, OR 1.51, 95 % CI 1.20–1.89, P < 0.001, I 2 = 37.7 %; AG vs. GG, OR 1.49, 95 % CI 1.01–2.21, P = 0.045, I 2 = 53.2 %; AA/AG vs. GG, OR 1.76, 95 % CI 1.35–2.30, P < 0.001, I 2 = 36.5 %). The sensitivity analysis further strengthened the validity of the positive association. Subgroup analysis of nine studies from Asian countries showed that there was a significant association between TNF-α 238 G/A polymorphism and increased risk of liver cancer in Asians (A vs. G, OR 1.35, 95 % CI 1.03–1.76, P = 0.027, I 2 = 40.2 %; AA/AG vs. GG, OR 1.56, 95 % CI 1.14–2.15, P = 0.006, I 2 = 41.9 %). In conclusion, TNF-α 238 G/A polymorphism is significantly associated with increased risk of liver cancer, especially in Asians.

Keywords

Liver cancer Tumor necrosis factor-α Polymorphism 

Notes

Conflicts of interest

None

References

  1. 1.
    El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–27.CrossRefPubMedGoogle Scholar
  2. 2.
    McCracken M, Olsen M, Chen Jr MS, Jemal A, Thun M, Cokkinides V, et al. Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin. 2007;57:190–205.CrossRefPubMedGoogle Scholar
  3. 3.
    Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma. Novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med. 2010;61:317–28.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology. 2011;140:1410–26.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48:2047–63.CrossRefPubMedGoogle Scholar
  6. 6.
    Shitani M, Sasaki S, Akutsu N, Takagi H, Suzuki H, Nojima M, et al. Genome-wide analysis of DNA methylation identifies novel cancer-related genes in hepatocellular carcinoma. Tumour Biol. 2012;33:1307–17.CrossRefPubMedGoogle Scholar
  7. 7.
    Yang CL, Jiang FQ, Xu F, Jiang GX. Adam10 overexpression confers resistance to doxorubicin-induced apoptosis in hepatocellular carcinoma. Tumour Biol. 2012;33:1535–41.CrossRefPubMedGoogle Scholar
  8. 8.
    Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer. 2007;7:599–612.CrossRefPubMedGoogle Scholar
  9. 9.
    Wullaert A, van Loo G, Heyninck K, Beyaert R. Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: effects on liver homeostasis and beyond. Endocr Rev. 2007;28:365–86.CrossRefPubMedGoogle Scholar
  10. 10.
    Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9:361–71.CrossRefPubMedGoogle Scholar
  11. 11.
    Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 2002;13:135–41.CrossRefPubMedGoogle Scholar
  12. 12.
    Walczak H. TNF and ubiquitin at the crossroads of gene activation, cell death, inflammation, and cancer. Immunol Rev. 2011;244:9–28.CrossRefPubMedGoogle Scholar
  13. 13.
    Wang Y, Kato N, Hoshida Y, Yoshida H, Taniguchi H, Goto T, et al. Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology. 2003;37:65–71.CrossRefPubMedGoogle Scholar
  14. 14.
    Kummee P, Tangkijvanich P, Poovorawan Y, Hirankarn N. Association of HLA-DRB1*13 and TNF-alpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population. J Viral Hepat. 2007;14:841–8.PubMedGoogle Scholar
  15. 15.
    Teixeira AC, Mendes-Junior CT, Souza FF, Ferreira SC, Deghaid NH, Castelli EC. Alleles and genotypes of IL-18 and TNF-α promoter polymorphisms are associated with higher risk of hepatocellular carcinoma (HCC) in Brazilian population. J Hepatol. 2010;52:S236.Google Scholar
  16. 16.
    Jeng JE, Tsai HR, Chuang LY, Tsai JF, Lin ZY, Hsieh MY, et al. Independent and additive interactive effects among tumor necrosis factor-alpha polymorphisms, substance use habits, and chronic hepatitis B and hepatitis C virus infection on risk for hepatocellular carcinoma. Medicine (Baltimore). 2009;88:349–57.CrossRefGoogle Scholar
  17. 17.
    Wang B, Wang J, Zheng Y, Zhou S, Zheng J, Wang F, et al. A study of TNF-alpha-238 and −308 polymorphisms with different outcomes of persistent hepatitis B virus infection in China. Pathology. 2010;42:674–80.CrossRefPubMedGoogle Scholar
  18. 18.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  19. 19.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMedGoogle Scholar
  20. 20.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Huang HL, Xie JS, Huang ZS, Zhao QZ. The relationship of polymorphism of tumor necrosis factor-α gene promoter-238G/A with primary hepatic carcinoma in patients. Progress of Anatomical Sciences. 2007;13:11–3 [article in Chinese].Google Scholar
  22. 22.
    Sakamoto T, Higaki Y, Hara M, Ichiba M, Horita M, Mizuta T, et al. Interaction between interleukin-1beta -31T/C gene polymorphism and drinking and smoking habits on the risk of hepatocellular carcinoma among Japanese. Cancer Lett. 2008;271:98–104.CrossRefPubMedGoogle Scholar
  23. 23.
    Ognjanovic S, Yuan JM, Chaptman AK, Fan Y, Yu MC. Genetic polymorphisms in the cytokine genes and risk of hepatocellular carcinoma in low-risk non-Asians of USA. Carcinogenesis. 2009;30:758–62.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Asim M, Malik A, Ahmad I, Khan NA, Kar P. Association of TNF alpha promoter polymorphism with an increased risk of hepatocellular carcinoma in North Indian population. Hepatol Int. 2011;5:428.Google Scholar
  25. 25.
    Jung KW, Ha E, Yu GI, Kim SJ, Chung WJ, Jang BK, et al. TNFalpha promoter polymorphism is a risk factor for susceptibility in hepatocellular carcinoma in Korean population. Clin Chim Acta. 2009;407:16–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Chen X, Zhang L, Chang Y, Shen T, Wang L, Zhuang H, et al. Association of TNF-alpha genetic polymorphisms with hepatocellular carcinoma susceptibility: a case–control study in a Han Chinese population. Int J Biol Markers. 2011;26:181–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Heneghan MA, Johnson PJ, Clare M, Ho S, Harrison PM, Donaldson PT. Frequency and nature of cytokine gene polymorphisms in hepatocellular carcinoma in Hong Kong Chinese. Int J Gastrointest Canc. 2003;34:19–26.CrossRefGoogle Scholar
  28. 28.
    Niro GA, Fontana R, Gioffreda D, Valvano MR, Lacobellis A, Facciorusso D, et al. Tumor necrosis factor gene polymorphisms and clearance or progression of hepatitis B virus infection. Liver Int. 2005;25:1175–81.CrossRefPubMedGoogle Scholar
  29. 29.
    Jeng JE, Tsai JF, Chuang LY, Ho MS, Lin ZY, Hsieh MY, et al. Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. Neoplasia. 2007;9:987–92.CrossRefPubMedGoogle Scholar
  30. 30.
    ten Hagen TL, Seynhaeve AL, Eggermont AM. Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed. Immunol Rev. 2008;222:299–315.CrossRefPubMedGoogle Scholar
  31. 31.
    Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin. 2008;29:1275–88.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol. 2008;26:3621–30.CrossRefPubMedGoogle Scholar
  33. 33.
    Zhu H, Zhang Z, Lei X, Feng J, Zhang F, Wang Y. Tumor necrosis factor alpha-308G>A, -863C>A, -857C>T gene polymorphisms and tuberculosis susceptibility: a meta-analysis. Gene. 2012;509:206–14.CrossRefPubMedGoogle Scholar
  34. 34.
    Ding B, Fu S, Wang M, Yue C, Wang W, Zhou D, et al. Tumor necrosis factor alpha −308 G>A polymorphisms and cervical cancer risk: a meta-analysis. Int J Gynecol Canc. 2012;22:213–9.CrossRefGoogle Scholar
  35. 35.
    Wang J, Cao C, Luo H, Xiong S, Xu Y, Xiong W. Tumour necrosis factor alpha -308G/A polymorphism and risk of the four most frequent cancers: a meta-analysis. Int J Immunogenet. 2011;38:311–20.CrossRefPubMedGoogle Scholar
  36. 36.
    Zhou P, Lv GQ, Wang JZ, Li CW, Du LF, Zhang C, et al. The TNF-alpha-238 polymorphism and cancer risk: a meta-analysis. PLoS One. 2011;6:e22092.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Xin Tian
    • 1
  • Ping Ma
    • 1
  • Chengguang Sui
    • 1
  • Yan Li
    • 1
  • Liye Fu
    • 1
  • Tao Jiang
    • 1
  • Yang Wang
    • 1
  • Youhong Jiang
    • 1
  1. 1.Molecular Oncology Department of Cancer Research Institution, The First HospitalChina Medical UniversityShenyangChina

Personalised recommendations